Insilico Medicine, backed by blue-chip investors like Warburg Pincus and Qiming Venture Partners, has 17 preclinical drug candidates so far and earlier this month signed a $500 million licensing deal with Italy’s Menarini.
While legacy pharma companies battle in court with government agencies over how to address the costs that result from antiquated drug development paradigms, a growing cadre of compute-enabled life science companies are unlocking the nascent power of next-generation compute technologies to transform drug discovery and development.